- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00506077
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is clinically stable, on current antipsychotic medication for at least 3 months and current dose for 2 months
- Patient has a 6th grade reading level or better
- Females are not pregnant, and those who can have children agree to remain abstinent or use acceptable birth control throughout the study
- Patient has had a stable living arrangement for at least 3 months prior to study start
- Patient is in general good health based on screening assessments
- Patient has total Positive and Negative Syndrome Scale (PANSS) score between 36 and 75 at screening and at the first baseline visit
- Patient has a Clinical Global Impressions - Severity (CGI-S) score less than or equal to 4 at screening and at the first baseline visit
Exclusion Criteria:
- Patient has a major disease/disorder that may interfere with cognitive testing (such as mental retardation) and/or pose a risk upon study participation
- Patient has a history of head trauma with loss of consciousness greater than 15 minutes
- Patient has had warfarin treatment, MAO inhibitors, clonazepam or clozapine within 1 month of screening
- Patient has had ECT treatment within 6 months of screening
- Patient requires treatment with antihistamines or certain other medications listed in the protocol
- Patient has a history of liver disease that has been active within the last 2 years, or a history of cancer within the past 5 years
- Patient has a history of alcohol or drug dependence within the past year or alcohol or drug abuse within 3 months of screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
|
Experimental: MK0249
|
MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline at 4 Weeks of Treatment in Total Cognitive Score on the Brief Assessment of Cognition in Schizophrenia (BACS) Battery.
Time Frame: Baseline and 4 weeks of treatment
|
The mean change from baseline after 4 weeks of treatment in total cognitive score on the BACS was calculated as a weighted average of T-scores (normalized for age) from BACS subtests including Verbal Memory, Digit Sequencing, Token Motor, Symbol Coding, Semantic Fluency, Letter Fluency, and Tower of London.
The minimum and maximum values possible for this composite T-score of the change from baseline were -131 and 131, respectively.
Higher values (positive changes from baseline) indicate better performance.
|
Baseline and 4 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline at 4 Weeks of Treatment in Attention/Processing Speed Composite Score
Time Frame: Baseline and 4 weeks of treatment
|
The Attention/Processing Speed Composite Score was comprised of the University of Pennsylvania's Computerized Neuropsychological Battery (CNP) Penn Continuous Performance Test (PCPT) and BACS battery Symbol Coding.
The composite score was calculated as a weighted average of the T-scores (normalized for age) for each test.
The minimum and maximum values possible for this composite T-score of the change from baseline were -91 and 91, respectively.
Higher values (positive changes from baseline) indicate better performance.
|
Baseline and 4 weeks of treatment
|
Mean Change From Baseline at 4 Weeks of Treatment in Episodic Memory Composite Score
Time Frame: Baseline and 4 weeks of treatment
|
The Episodic Memory Composite Score was comprised of the University of Pennsylvania's Computerized Neuropsychological Battery (CNP) Face Memory and BACS battery Verbal Memory.
The composite score was calculated as a weighted average of the T-scores (normalized for age) for each test.
The minimum and maximum values possible for this composite T-score of the change from baseline were -202 and 202, respectively.
Higher values (positive changes from baseline) indicate better performance.
|
Baseline and 4 weeks of treatment
|
Mean Change From Baseline at 4 Weeks of Treatment in Working Memory Composite Score
Time Frame: Baseline and 4 weeks of treatment
|
The Working Memory Composite Score was comprised of the University of Pennsylvania's Computerized Neuropsychological (CNP) battery N-back test and the BACS battery Digit Sequencing test.
The composite score was calculated as a weighted average of the T-scores (normalized for age) for each test.
The minimum and maximum values possible for this composite T-score of the change from baseline were -122 and 122, respectively.
Higher values (positive changes from baseline) indicate better performance.
|
Baseline and 4 weeks of treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre-randomization Baseline: Total Cognitive Score on the Brief Assessment of Cognition in Schizophrenia (BACS) Battery.
Time Frame: Pre-randomization Baseline
|
Pre-randomization baseline values for all treatment sequences are equal because the constrained longitudinal data analysis (cLDA) model was used (Liang and Zeger, 2000, Sankhya: The Indian Journal of Statistics, Series B 62, 134-148). |
Pre-randomization Baseline
|
Pre-randomization Baseline: Attention/Processing Speed Composite Score
Time Frame: Pre-randomization Baseline
|
Pre-randomization baseline values for all treatment sequences are equal because the constrained longitudinal data analysis (cLDA) model was used (Liang and Zeger, 2000, Sankhya: The Indian Journal of Statistics, Series B 62, 134-148). |
Pre-randomization Baseline
|
Pre-randomization Baseline: Episodic Memory Composite Score
Time Frame: Pre-randomization Baseline
|
Pre-randomization baseline values for all treatment sequences are equal because the constrained longitudinal data analysis (cLDA) model was used (Liang and Zeger, 2000, Sankhya: The Indian Journal of Statistics, Series B 62, 134-148). |
Pre-randomization Baseline
|
Pre-randomization Baseline: Working Memory Composite Score
Time Frame: Pre-randomization Baseline
|
Pre-randomization baseline values for all treatment sequences are equal because the constrained longitudinal data analysis (cLDA) model was used (Liang and Zeger, 2000, Sankhya: The Indian Journal of Statistics, Series B 62, 134-148). |
Pre-randomization Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0249-016
- 2007_522
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paranoid Schizophrenia
-
Mental Health Services in the Capital Region, DenmarkCentral Denmark Region; Mental Health Services in the North Denmark RegionActive, not recruitingPsychotic Disorders | Schizophrenia and Related Disorders | Schizotypal Disorder | Schizophrenia Prodromal | Paranoid Schizophrenia | Paranoid Ideation | Paranoid Delusion | Ideas of Reference | Psychosis Paranoid | Psychotic Paranoia | Psychotic; Disorder, DelusionalDenmark
-
Merck Sharp & Dohme LLCCompletedSchizophrenia | Paranoid Schizophrenia
-
Weill Medical College of Cornell UniversityNational Alliance for Research on Schizophrenia and DepressionCompleted
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
CEDIARA - Assoc. Solidariedade Social de Ribeira...CompletedPsychotic Disorders | Schizophrenia | Schizoaffective Disorder | Delusional Disorder | Substance-Induced Psychotic DisorderPortugal
-
King's College LondonCompletedParanoia | Schizophrenia-spectrum DiagnosisUnited Kingdom
-
Weill Medical College of Cornell UniversityCompletedSchizophrenia | Delusional DisorderUnited States
-
Mental Health Services in the Capital Region, DenmarkTrygFonden, Denmark; Odense Patient Data Explorative NetworkCompletedSchizophrenia, Schizotypal and Delusional DisordersDenmark
-
German Research FoundationUnknownSchizophrenia | Delusional Disorders (ICD-10)Germany
Clinical Trials on MK0249
-
Merck Sharp & Dohme LLCCompletedAlzheimer's Disease
-
Merck Sharp & Dohme LLCTerminatedSleep Apnea, Obstructive | Hypopnea Syndrome | Excessive Daytime Sleepiness
-
Merck Sharp & Dohme LLCCompletedAttention-Deficit/Hyperactivity Disorder (ADHD)